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Abstract 
 
In this review, we explore the evolving evidence linking physiological assessment 
of coronary artery disease with plaque progression and vulnerability. Reducing 
clinical events including acute coronary syndromes (ACS) remains the ultimate 
goal for diagnostic tests and we highlight evidence supporting their use as 
predictors of patients at risk of adverse clinical events. Historical and 
contemporary studies support synergy between lesion severity, ischemia, plaque 
vulnerability and patient prognosis. Ischemia contributes to clinical events 
through association with plaque burden, however we review the emerging 
concept that it signifies disturbed lesion hemodynamics with a role in 
atherothrombosis. Biomechanical pathophysiological forces including endothelial 
shear stress – the frictional force generated by blood flow on the vessel wall – are 
increasingly linked with atherogenesis, vulnerable plaque morphology in addition 
to platelet and leucocyte activation. We conclude by transitioning from the model 
of the vulnerable plaque to the concept of the 'vulnerable patient' looking more 
broadly at physiological contributors to Virchow's triad underpinning ACS. 
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Abbreviations 
ACS – Acute coronary syndrome 
APS – Axial plaque stress 
AMI – acute myocardial infarction 
CFD – Computational fluid dynamics 
CCTA - coronary computed tomography angiography  
DS – diameter stenosis 
ESS – Endothelial shear stress 
FFR – Fractional flow reserve 
MACE – Major adverse cardiac event 
TCFA - Thin-cap fibroatheroma 
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Introduction 
 
The fractional flow reserve (FFR) reflects the extent to which maximal 
myocardial flow is decreased due to the presence of an epicardial narrowing.(1,2)  
Revascularization decisions based on FFR improve prognosis in patients with 
coronary artery disease.(3,4) Moving beyond flow-limitation, the anatomical and 
physiological characteristics of a plaque implicate a role for physiological factors 
and biomechanical forces in the pathophysiology of plaque rupture.(5) 
Endothelial shear stress – the frictional force generated by blood flow on the 
vessel wall – is increasingly linked with atherogenesis and plaque vulnerability in 
addition to platelet and leucocyte activation.(6,7) While coronary physiologic 
indices such as FFR have been proposed for interrogation of the ischemic 
potential of stable coronary stenoses, lesion hemodynamics are associated with 
atherosclerotic plaque biology and vulnerability.(8)  
 
Coronary physiologic data may be integrated with anatomical information from 
coronary angiography and intravascular imaging to provide novel insights into 
lesion pathobiology with potential to better inform the treatment of coronary 
disease. In this review, we will explore the evolving evidence linking 
physiological assessment of coronary artery disease with plaque progression and 
vulnerability.  
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1 - Ischemia based on anatomic evaluation (invasive coronary 
angiography) 
 
Coronary angiography for detecting plaque and assessing vulnerability   
 
Luminal changes demonstrable on coronary angiography have traditionally been 
used to determine whether a coronary stenosis is of hemodynamic significance 
i.e. associated with myocardial ischemia. However, x-ray angiography is merely a 
‘luminogram’ and estimating physiological significance from diameter stenosis 
(DS) is fraught with many pitfalls: the ratio of the minimum luminal diameter to 
the adjacent normal segment ignores the facts that atherosclerosis is a diffuse 
disease and angiography alone is often unable to distinguish between normal and 
diseased segments.(9) The Glagov phenomenon of positive vessel remodeling 
may obfuscate plaque within the vessel wall without causing lumen 
encroachment. Histopathological studies show that luminal narrowing typically 
occurs late after the atheroma expands to around 45% plaque burden by cross-
sectional area (the limit of external elastic media expansion).(10) Despite 
advances in quantitative coronary angiography (QCA) techniques, there are well 
recognized limitations of angiography in determining the hemodynamic 
significance of intermediate coronary lesions (40-70% DS).(11)  
 
The relationship between lesion severity and vulnerability  
Only a minority of early atherosclerotic plaques progress to high-risk thin-cap 
fibroatheroma (TCFA) which are thought to be the most common precursors to 
ruptured plaques.(12) Non-obstructive plaques are more prevalent than 
obstructive plaques, however the absolute risk of plaque rupture is higher with an 
obstructive lesion.(8,13) Contemporary angiographic studies support that at the 
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time of myocardial infarction the underlying lesion on angiography is usually 
severely stenotic (Mean DS 66+/-12%).(14) Post mortem data confirms the 
majority of lesions causing fatal infarction are obstructive when plaque burden is 
analyzed by histopathological cross-sectional area: more than 75% stenosis is seen 
in 70% of plaque ruptures.(15) It is likely that rapid, though usually asymptomatic 
progression and resultant stenosis/thrombosis occurs in the days-to-weeks 
preceding AMI such that acute total vessel occlusion typically develops at the site 
of an obstructive narrowing.  
Studies of non-invasive angiography using CCTA strongly support that the larger 
plaque size associates with lesion vulnerability.(16) Other high risk 
atherosclerotic plaque features on CCTA include positive vessel remodeling, low-
attenuation plaques, ‘napkin-ring’ sign, and spotty calcification (17,18). 
The PROSPECT study of the natural history of atherosclerosis using 
intravascular ultrasound (IVUS) is the single most important contemporary 
evidence and supports the notion that events are linked with lesion severity. 
Plaque burden ≥70% was the strongest predictor of future events (hazard ratio 
[HR]: 5.03; p < 0.001). Minimal luminal area (MLA) was also an important 
independent predictor.(13) Lesions with plaque burden ≥70% had event rates of 
almost 10% over a median follow up of 3.4 years. These may not always appear 
obstructive on conventional angiography in keeping with the Glagov 
phenomenon and the accepted limitations of angiography.(10) There was not a 
single event arising from a coronary artery segment with <40% plaque burden. 
Analysis of non-culprit lesions in PROSPECT that were responsible for future 
MACE showed that the majority of these plaques were non-obstructive on 
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baseline angiography (mean diameter stenosis (DS), 32.3±20.6%), but later at the 
subsequent event the angiographic severity in this subgroup had progressed to a 
mean DS of 65%. Importantly, the dominant driver of these events was 
progression of angina; the more robust clinical end-point of AMI in a non-culprit 
vessel occurred in less than 1% of patients. Taken together, the most likely model 
of vulnerable plaques is that of step-wise accelerated progression with subclinical 
plaque ruptures and increasing lumen encroachment, with a continuum of both 
obstructive and non-obstructive plaques underlying ACS.(19)  
2 - Ischemia based on functional evaluation  
The adverse prognostic impact of ischemia has been well established using 
various imaging modalities for non-invasive functional assessment. Myocardial 
ischemia identified on single-photon emission computed tomography (SPECT) is 
strongly predictive of major adverse cardiac events (MACE) in both symptomatic 
and asymptomatic individuals.(20,21) Comprehensive follow up data from 
almost 70,000 myocardial perfusion scans highlights the high rates of MACE 
with moderate to high risk ischemia on SPECT compared with low risk – up to 
8.5% per annum versus 0.6%.(22) Studies using stress perfusion cardiac magnetic 
resonance (CMR) offer additional insights owing to superior spatial resolution 
and enhanced classification of inducible ischemia and myocardial scar. Out of 
1,152 patients with angina followed up after stress perfusion CMR, those with 
inducible ischemia suffered MACE at 3.9%/year compared with only 1% in those 
with negative scans. On multivariate analysis, ischemia was the strongest 
independent predictor of cardiac death, nonfatal myocardial infarction, and 
stroke at mean follow up of 4.2 years (HR 3.21, 95% CI 2.06–5.00; 
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P<0.0001).(23) Furthermore recent CMR data suggests the presence of an 
‘ischemic threshold’ whereby a burden of 1.5 ischemic segments was 
independently associated with nearly 9-fold increased risk of cardiac death, MI, 
or late coronary revascularization during a mean follow-up of 2.5 years.(24) 
Importantly, even when left ventricular function and myocardial scar burden 
were accounted for, this ‘ischemic threshold’ remained the strongest independent 
predictor of ‘hard’ clinical end-points - cardiac death and MI. 
Ischemia may be a surrogate marker for anatomical plaque burden – indeed the 
COURAGE trial highlighted the intuitive interaction between ischemia on 
SPECT and anatomical disease burden on baseline angiography (p=0.03). Taken 
together, the COURAGE data showed anatomic disease burden to be a more 
consistent predictor of events compared with ischemia.(25),(26) Importantly, this 
study overlooked the fact that the degree of ischemia was determined before 
treatment. The influence of ischemia on outcome should be at least partly 
annulled following initiation of treatments aimed at alleviating its existence - thus 
it is unsurprising that plaque burden was more predictive of events. The 
COURAGE nuclear substudy did not show that ischemia was associated with 
risk of future events, however it was not powered to perform this non pre-
specified analysis and may have been affected by selection bias.(27) Other 
contemporary cohorts have found ischemia on SPECT to be the strongest 
predictor of events, providing complementary additional information to the 
anatomical disease burden assessed by coronary artery calcium score.(28) 
Amongst patients with previous revascularization, the residual ischemic burden is 
the strongest independent predictor of future events, consistently identifying high-
risk patients in groups with similar degrees of anatomical plaque burden.(29,30)  
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Lessons from FAME – is FFR a predictor of lesion vulnerability?  
The FAME-II study (FFR versus Angiography for Multivessel Evaluation II) 
showed that patients with functionally significant lesions (FFR≤0.80) had 
superior outcomes with PCI and optimal medical therapy compared with optimal 
medical therapy alone.(3) Critics argue that urgent revascularizations were to be 
expected in this trial given that both patients and physicians were potentially 
aware of the significant lesions that were not stented. This may have lowered the 
threshold for urgent revascularization in patients with FFR-positive stenosis in 
the medical therapy group. Besides the fact that this phenomenon did not happen 
in the registry patients (also aware of the presence of untreated lesions), half of 
the urgent revascularizations occurred in the context of positive biomarkers or 
new ECG changes, while 80% occurred in patients with these findings or rest 
angina. A blinded and independent clinical event committee adjudicated all these 
events. In addition, it is very likely that the large number of unplanned 
revascularizations in patients randomized to medical therapy actually limited the 
number of “hard end-points” (death or myocardial infarctions). The two-year 
follow up data showed that after excluding the potentially more benign peri-
procedural myocardial infarctions, the incidence of death or myocardial 
infarction was lower in the PCI group than in the medical-therapy group (4.6% 
vs. 8.0%, p=0.04).(3) There was a significantly lower incidence of 
revascularization procedures triggered by ECG changes or MI in the PCI group 
than in the medical-therapy group (3.4% versus 7.0%, p=0.01). 
Equally, FAME and now 15-year follow-up data from the DEFER study 
highlight the negative predictive value of FFR: non-ischemic stenosis have an 
excellent prognosis on medical therapy with <1% annualized incidence of 
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MI.(31) The study also reinforces the known adverse prognostic implications of 
ischemia: lower FFR values are associated with over double the rates of 
death/MI (Figure 1).(32)  
Figure 1 - Adverse prognostic implications of ischemia -  Cardiac death and 
acute myocardial infarction rate in the 3 groups of the DEFER study after a 
follow-up of 5 years. (Reprinted from Pijls et al(32) with permission of the 
publisher. Copyright © 2007, Elsevier). 
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Moreover, the outcome in the FAME 2 registry group (FFR>0.8) at two years 
was identical to that observed in the PCI group. Further comprehensive evidence 
for the relationship between physiological lesion severity measured by the FFR 
and clinical outcomes was demonstrated in a large meta-analysis.(33) Johnson et 
al used study-level and raw patient-level data from all published studies of FFR 
with prospective clinical follow up for MACE, elegantly plotting risk of MACE 
using cox modelling as a function of FFR modulated by therapeutic choice 
(medical therapy/revascularization). Barbato et al recently provided further 
analysis from the FAME-2 study showing the natural history of events according 
to FFR in patients who did not undergo revascularisation . They showed a step-
up increase in the rates of MACE by decreasing FFR values (Figure 2).(34)  
Figure 2 - MACE rates at 2 years in FAME 2 patients randomized to medical 
therapy. (Reprinted from Barbato et al(34) with permission of the publisher. 
Copyright © 2016, Elsevier). 
 
 
These findings are consistent with the hypothesis that FFR assists in the 
prediction of plaque behaviour: the ischemic potential of a lesion may be a 
surrogate marker of plaque vulnerability with its attendant risk of rupture. It is 
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important to note that a lower absolute value of FFR corresponds with a higher 
risk of events, however risk stratification using this approach does not necessarily 
detect which ischemia producing lesion will drive events. Prospective studies 
have shown that up to half of future MACE relates to non-target vessels, but a 
large proportion of the future MACE is attributable to the lesion’s FFR. Stenting 
these hemodynamically significant vulnerable lesions may prevent future 
coronary events.(33) 
 
How ischemia affects plaque vulnerability and propensity to ACS 
There are two main reasons for why an ischemia-producing lesion is more likely 
to cause ACS than a non-ischemia-producing lesion. First, an obstructive stenosis 
that limits blood flow is more likely to become occlusive leading to an acute MI 
as the burden of plaque increases (plaque progression). Second, the increasing 
stenosis severity leads to changes in flow dynamics and wall shear stress which in 
turn increase the likelihood of plaque rupture.(8) Versteeg et al. demonstrated that 
the responses and expression of monocyte toll-like receptors 2 and 4, which are 
thought to be related to plaque vulnerability, are significantly greater in patients 
with an FFR <0.75 compared with patients with an FFR of >0.80.(35) 
 
Recent data has shown that the fibrous cap thickness (FCT) of intermediate grade 
lipid-rich plaques correlates with the physiological significance of the lesion 
(FFR<0.8).(36) A positive FFR is strongly predictive of a thin-capped 
fibroatheroma (<80 microns). Histopathological studies suggest that vulnerable 
plaques are those with a cap thickness of <65 microns, more recent in-vivo OCT 
data supports the FFR-predicted critical cap thickness value of <80 microns.(37) 
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Importantly, rupture of these thin caps overlying vulnerable plaques is the cause 
of 75% of ACS.(38) There is a wealth of evidence supporting the role of more 
severe (and likely ischemia producing lesions) to be more dangerous. ROMICAT-
II showed stenosis severity on CCTA to be the strongest predictor of ACS in 
acute chest pain.(39) Multivariate analysis from a cohort of over 3000 patients 
undergoing CCTA showed that whilst non obstructive plaques were almost 4 
times more prevalent than obstructive ones, stenotic lesions were stronger 
predictors of ACS (HR: 3.2: 95% CI: 2.11–5.00; p<0.0001).(40) In ACS patients 
studied with IVUS & OCT severely stenotic areas had TCFA with more features 
of plaque vulnerability.(41) Pathology studies have shown that plaques are 
constantly rupturing and healing and when this happens over a non-severely 
obstructing lesion it is more likely to be silent.(42) Ruptured TCFA with 
thrombus formation superimposed on a severe stenosis is more likely to limit the 
coronary blood flow (and lead to clinical events) than the same event 
superimposed on a non-severe stenosis.  
3 – Biomechanical pathophysiological forces including endothelial 
shear stress 
 
Blood flow within a conduit artery exerts three distinct types of biomechanical 
strain on the vessel: axial, circumferential, and shear stress. Stress is a reflection 
of force normalized per unit area (Newtons per square meter or Pascals or dynes 
per square centimeter; 1 N/m2 = 1 Pa =10 dyn/cm2). Endothelial shear stress 
(ESS) is the most studied of these forces and appears to be the most fundamental 
and robust predictor of atherosclerotic initiation and development.(43) ESS is the 
tangential force exerted on the vessel wall attributable to the friction of blood flow 
on the endothelial surface (Figure 3 – central illustration). These endothelial cells 
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are incredibly sensitive to ESS and regulate vascular function in health and 
disease through mechanotransduction. Axial plaque stress (APS) is a longitudinal 
mechanical force applied along the length of plaque resulting from arterial blood 
pressure and stretching with phasic cardiac motion. APS occurs at force 103-105 
times greater than ESS and thus may be the biomechanical factor more causally 
related to plaque rupture. Challenges with in-vivo estimation may partly explain a 
relative paucity of research into its contribution to atherosclerotic plaque 
pathophysiology compared to ESS. Computerised modelling demonstrates that 
lesions with similar angiographic and hemodynamic severity can have hugely 
variable levels of axial plaque stress potentially accounting for differences in 
vulnerability relating to lesion geometry of the upstream or downstream shoulder 
(radial gradient). (44)  
Figure 3: Central Illustration - Ischemic and physiological factors contributing to plaque vulnerability 
 
 
How is ESS estimated in vivo? 
The derivation of ESS depends on computational fluid dynamics (CFD) - 
incorporating flow data (often obtained from invasive Doppler wire) into 3D 
computerised models of coronary arteries. These reconstructions may be created 
from biplane or 3D coronary angiography and even integrated with intravascular 
imaging for more accurate vascular profiling.(45) CFD has recently been 
combined with coronary computed tomography angiography (CCTA) facilitating 
a non-invasive way of estimating shear stress.(46,47) ‘Virtual FFR’ (FFR-CT) can 
be obtained from 3D coronary reconstructions from CCTA using CFD modelling 
and have been shown to reduce cost and unnecessary invasive procedures in 
patients with stable angina.(48) 
How does shear relate to plaque biology and vulnerability? 
Caro et al first described the pathological role of low and oscillatory ESS, forming 
the hypothesis which is now the consensus mechanism for the initiation of 
atherosclerosis.(6,49,50) Coronary arteries with undisturbed flow and 
physiological ESS facilitate endothelial cell expression of atheroprotective genes 
and the suppression of pro-atherogenic genes leading to coronary plaque 
quiescence and stability. However in areas of disturbed low flow with low ESS, 
atheroprotective genes are down-regulated and pro-atherogenic genes up-
regulated resulting in acceleration of atherogenesis.(43,51) Mechanoreceptors on 
the endothelial cell surface respond to low ESS stimuli leading to mechano-
sensitive gene expression promoting atherosclerosis.(51) Reviewing the details 
nature of these mechanisms is outside the scope of this review, however there are 
a number of complex molecular and cellular signaling pathways outlined in the 
central illustration (Figure 3).  
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Thombotic milieu: emerging relationship between shear stress and platelet 
activation 
Platelet aggregation is a physiological prerequisite at sites of arterial injury to 
arrest bleeding allowing for arterial repair. Nevertheless, an exaggerated platelet 
response at the site of a stenotic vulnerable plaque can lead to acute coronary 
syndrome. Platelets preferentially adhere to the low shear stress zones (typically 
located at the downstream face) forming thrombi as a consequence of disturbed 
blood flow hemodynamics.(52) Yong et al showed in humans that coronary 
artery stenosis severity correlates with shear stress and markers of platelet 
activation. (7)  Shear appears to be a critical determinant of platelet activation 
and thus an important determinant of plaque vulnerability and propensity to 
acute coronary syndrome. 
Relationship between shear stress, plaque progression and rupture  
Depending on the plaque shape, a stenosis results in a concomitant spread of ESS 
with relatively low ESS occurring in the upstream shoulder of the plaque, high 
ESS at the most stenotic site of the plaque, and low oscillatory ESS at the 
downstream shoulder.(6,53) A sustained low ESS environment drives excessive 
inflammation, lipid accumulation and matrix degradation leading to fragility and 
a propensity to rupture. These sites demonstrate augmented mRNA expression 
with increased expression of matrix-degrading proteases thereby shifting plaque 
progression towards atheroma with a thin fibrous cap.(54) Positive (expansive) 
remodeling maintains luminal patency at the expense of perpetuating a low ESS 
environment locally, allowing ongoing lipid accumulation and inflammation and 
enhancing the plaque’s vulnerable characteristics.(55) In-vivo human studies 
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using CT derived coronary artery reconstructions highlights lower average wall 
shear stress to be a sensitive predictor of plaque location.(56) More recently OCT 
vascular profiling after ACS showed coronary regions exposed to low ESS are 
associated with larger lipid burdens, thinner fibrous caps and a higher prevalence 
of TCFA.(57) Low ESS was associated with increased plaque burden on 
longitudinal follow up.  In contrast, high ESS at the site of maximal stenosis may 
increase the strain and erosion of the fibrous cap with increased thrombogenicity 
and the potential for plaque destabilization.(58,59) In-vivo imaging of culprit 
arteries using IVUS supports a role of high ESS in fibrous cap rupture.(60)  
 
Prospective in-vivo studies of atherosclerosis have only limited accuracy in 
predicting future events based on anatomical plaque characteristics 
alone.(13,61,62) The PREDICTION study is the largest prospective observational 
study of wall shear stress and morphology on clinical outcome allowing insights 
into the natural history of coronary atherosclerosis. A combination of low local 
ESS, large plaque burden, and a large necrotic core gave a positive predictive 
value of 53% for identifying coronary lesions leading to cardiac events. Low ESS 
was an independent predictor of worsening luminal obstruction both in the 
natural history of CAD and in the development of clinically relevant lesions 
treated with PCI.(63)  
In summary, low ESS is a pathophysiological parameter important in localization 
of plaque burden and also correlates with features of vulnerability. High ESS may 
occur concurrently at the ‘neck’ of a stenosis increasing in magnitude with 
progressive lumen encroachment. This enhances local thrombogenicity and 
triggers molecular pathways implicated in fibrous cap disruption increasing the 
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probability of clinical manifestation as ACS.  
Future directions: natural history of plaques, inflammation and 
plaque vulnerability 
 
 The pathobiology of atherosclerotic lesions is a dynamic process (Figure 4). 
Figure 4: Contemporary premise on the natural history of coronary plaques: drivers towards ACS include local 
features of plaque vulnerability combined with systemic inflammatory factors and thrombotic milieu in the 
vulnerable patient
TCFA are common and can be found in the majority of patients presenting with 
ACS.(37,64) Nevertheless, the risk of an individual TCFA causing ACS is small and the 
nature history of these lesions varies from an indolent course, transforming into more 
stable plaque types(65) or alternatively progressive luminal obstruction may occur in 
step-wise fashion following asymptomatic rupture.(66,67) In-vivo and pathological 
studies support the concept that plaque ruptures are more likely to be symptomatic if 
they occur at the site of a severe stenosis with resultant thrombus potentiating abrupt 
vessel occlusion.(15,68)  
The translation of a ‘vulnerable plaque’ to a ‘vulnerable patient’ involves all 3 
components of Virchow’s triad: altered coagulation/thrombosis, endothelial dysfunction 
and hemodynamic factors. This concept of the ‘vulnerable patient’ is key; efforts to treat 
the entire diffuse atherosclerotic process medically is paramount.(69) Intravascular 
imaging techniques allow for detailed lesion characterization but have not been proven 
to reduce events by directing percutaneous treatment (e.g. PCI). This reflects the 
dynamic nature of intracoronary plaques and low specificity of intravascular imaging in 
predicting lesion-specific future MACE. FFR is currently the most robust tool in 
identifying lesions with ischemic potential (often correlating with markers of plaque 
vulnerability) allowing targeted intervention in symptomatic patients with the aim of 
reducing future MACE. 
Conclusion 
 
Plaque vulnerability may result from the hemodynamic perturbations and altered 
biomechanical forces which associate with the functional significance of a coronary 
artery stenosis (and downstream ischemia). There is interplay and synergy between the 
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degree of luminal obstruction, ischemia, shear stress, activation of blood cells and 
subsequent vascular remodeling. Plaque vulnerability is determined by more than 
anatomy: coronary physiology is a predictor of plaque behavior and complements 
information from angiography identifying high-risk lesions and guiding revascularization 
to optimize patient outcomes. Future refinements in the use of coronary physiology may 
prove useful in the identification and treatment of both the vulnerable plaque and 
vulnerable patient. 
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Figure Legends 
 
 
Figure 1: Adverse prognostic implications of ischemia -  Cardiac death and acute 
myocardial infarction rate in the 3 groups of the DEFER study after a follow-up of 5 
years. (Reprinted from Pijls et al(32) with permission of the publisher. Copyright © 2007, 
Elsevier). 
 
Figure 2: MACE rates at 2 years in FAME 2 patients randomized to medical therapy - 
This figure illustrates the rate of major adverse cardiovascular events (MACE) at 2 years 
of follow-up by 0.05 strata of fractional flow reserve (FFR) values. There is a step-up 
increase in the rates of MACE by decreasing FFR values. This increase is steeper below 
an FFR of 0.80 and plateaus below an FFR of 0.60. (Reprinted from Barbato et al(34) 
with permission of the publisher. Copyright © 2016, Elsevier). 
 
Figure 3: Ischemic and physiological factors contributing to plaque vulnerability. This 
schematic demonstrates the links between coronary physiology, haemodynamic sheer 
forces and pathophysiology of plaque vulnerability. 
MMP = matrix metalloproteinase; ROS = reactive oxygen species; NO = nitric oxide; 
SMC = smooth muscle cell; VCAM = vascular cell adhesion molecule; IL = interleukin; 
IFN = interferon; TNF = tumor necrosis factor; LDL = low-density lipoprotein 
cholesterol; PDGF = platelet-derived growth factor; VEGF = vascular endothelial 
growth factor. 
 
Figure 4: Contemporary premise on the natural history of coronary plaques: drivers 
towards ACS include local features of plaque vulnerability combined with systemic 
inflammatory factors and thrombotic milieu in the vulnerable patient 
